Merck mulling more M&A - reports

Wednesday, 19. June 2019 12:20

Pharmaceutical giant Merck & Co. Inc. is looking for more small- and mid-sized deals to expand its portfolio of cancer treatments, the Wall Street Journal reported on Wednesday citing sources familiar with the matter.

The company's aim is to both capitalize on the strength of its top-selling Keytruda product and to further broaden its non-oncology products, according to the sources. They added that Merck is also interested in similarly-sized deals that would complement its vaccine offerings and animal-health medicines. The pharmaceutical giant is expected to address the concerns and outline its strategy when it holds its first investor day in five years on Thursday.

Merck announced last week that it will buy biopharmaceutical company Tilos Therapeutics for up to $773 million. It also previously said in May that it will acquire cancer treatment developer Peloton Therapeutics Inc. for $1.05 billion.

Related Links: Merck KGaAMerck & Co. Inc.
Breaking the News / DZ